Turbinoplasty — Procedure Guide, Recovery & Risks | MyMedicPlus

Turbinoplasty — also called inferior turbinate reduction or turbinate surgery — is a surgical procedure performed to reduce the size of pathologically enlarged inferior nasal turbinates, which are bony shelf-like projections on the lateral wall of the nasal cavity covered by a highly vascular and gland-rich mucosal lining. The inferior turbinates are the most important structures for regulating nasal airflow, humidifying and warming inspired air, and filtering particulate matter; however, when chronically hypertrophied — enlarged beyond their normal size — they cause significant and persistent nasal obstruction, impaired nasal breathing, mouth breathing, and impaired olfaction. Inferior turbinate hypertrophy may be bony (hypertrophy of the underlying turbinate bone), mucosal (chronic oedema of the overlying soft tissue), or combined. Chronic allergic rhinitis is the most common cause, triggering persistent parasympathetic stimulation and inflammatory mucosal oedema; other causes include non-allergic rhinitis, drug-induced rhinitis medicamentosa (from overuse of topical decongestants such as oxymetazoline), hormonal rhinitis in pregnancy, and structural deviated septum causing compensatory contralateral turbinate hypertrophy. Multiple surgical techniques are available to reduce turbinate volume, each with different mechanisms, preservation of mucosal function, and recurrence profiles, tailored to the underlying structural anatomy and the patient's prior treatment history.

Turbinoplasty is indicated for patients with chronic nasal obstruction caused by inferior turbinate hypertrophy that has not responded to an adequate trial of medical management lasting at least 3 months. Medical management includes intranasal corticosteroid sprays (first-line treatment), antihistamines for allergic rhinitis, saline nasal irrigations, and a short course of decongestants. Patients suitable for surgery typically present with persistent bilateral nasal blockage, mouth breathing, sleep disruption, snoring, reduced sense of smell, and fatigue from poor sleep quality. Nasal endoscopy and optionally CT of the sinuses confirms the degree of turbinate enlargement and rules out coexisting pathology such as nasal polyps, deviated septum, or sinusitis. Turbinoplasty is frequently performed in combination with septoplasty (to correct a deviated nasal septum) in patients with combined obstructive anatomy, and may accompany functional endoscopic sinus surgery (FESS) for concurrent sinus disease.

Turbinoplasty is performed under general anaesthesia as a day-case procedure — typically in combination with septoplasty if concurrent nasal septal deviation is present — or under local anaesthesia with intravenous sedation in selected patients. Multiple surgical techniques exist, chosen based on the predominant component of hypertrophy (bony vs mucosal), surgeon preference, and available equipment. Submucous diathermy (SMD): a monopolar or bipolar diathermy needle is inserted submucosally along the length of the turbinate and activated as it is withdrawn, causing interstitial fibrosis that progressively reduces mucosal volume over 4-6 weeks; this is the simplest technique but has the highest recurrence rate. Radiofrequency coblation (Coblator): a radiofrequency probe is inserted submucosally; coblation energy causes tissue ablation at lower temperatures than conventional diathermy (40-70 degrees C vs over 200 degrees C), reducing surrounding mucosal thermal injury and preserving the ciliated surface epithelium. Microdebrider-assisted turbinate reduction (MAT or MATRD): a powered microdebrider device resects turbinate tissue from within a tunnel created under the mucoperiosteum, removing bone and submucosa while preserving the overlying mucosa; this provides precise volume reduction with preservation of mucociliary function. Outfracture (lateralisation): the turbinate is fractured laterally and out-of-position using an elevator, widening the airway without tissue removal; this is most effective for bony hypertrophy and is often combined with submucous resection. Partial inferior turbinectomy (excision of the anterior head or inferior free edge) provides more definitive volume reduction but risks atrophic rhinitis if excessive tissue is removed. All techniques take 15-30 minutes per side.

Turbinoplasty significantly improves nasal airflow and subjective breathing quality in over 75-85% of patients with objectively confirmed inferior turbinate hypertrophy, with sustained benefit at 12 months. Improvements in nasal airway resistance are demonstrable on acoustic rhinometry and nasal peak flow measurement. Microdebrider-assisted turbinate reduction and radiofrequency coblation achieve comparable symptom improvement rates to partial turbinectomy but with lower rates of post-operative bleeding, crusting, and mucociliary dysfunction due to mucosal preservation. Reduction of turbinate volume relieves mouth breathing, reduces snoring severity in many patients, improves exercise tolerance, and enhances the efficacy of topical nasal steroid sprays by allowing better drug deposition in the nasal cavity. When combined with septoplasty for concurrent septal deviation, combined septorhinoplasty achieves objective improvement in nasal breathing in over 85% of patients. Symptoms of co-existing allergic rhinitis are addressed concurrently with pharmacotherapy (intranasal corticosteroids, antihistamines, allergen immunotherapy) to address the underlying inflammatory driver of turbinate hypertrophy and minimise recurrence risk.

Primary post-operative bleeding (within 24 hours) requires emergency packing or cautery in approximately 1–3% of cases. Secondary bleeding at 7–10 days when crusts separate is less common but may be alarming. Excessive submucosal tissue removal risks atrophic rhinitis (ozaena) — a severe complication characterised by mucosal atrophy, paradoxical nasal obstruction despite wide airways, foul-smelling crusting, and loss of smell — which is why mucosal-preserving techniques are strongly preferred. Infection is uncommon but may cause crusting and delayed healing. Adhesion formation (synechia between the turbinate and the nasal septum or lateral wall) occurs in 1–5% of cases, particularly after concurrent septoplasty. Temporary or rarely permanent reduction in olfaction has been reported. Symptom recurrence requiring revision surgery occurs in 10–20% of patients within 5 years, higher with radiofrequency ablation compared with microdebrider reduction.

Nasal packing or dissolvable dressing, if placed, is removed at 24–48 hours in clinic or dissolves spontaneously. Nasal congestion, crusting, bloodstained discharge, and mild facial pressure are expected for 2–4 weeks as mucosal healing progresses. Saline nasal irrigations (using a neti pot or nasal rinse bottle) performed 2–3 times daily are essential to clear crusts, maintain nasal hygiene, and support mucosal healing. Strenuous exercise, swimming, and nose-blowing against resistance are avoided for 2–3 weeks. Antihistamines and intranasal corticosteroid sprays are typically resumed at 2 weeks. The benefit of surgery becomes fully apparent at 4–6 weeks once post-operative swelling has subsided and mucosal healing is complete. A follow-up nasal endoscopy is recommended at 6 weeks. Ongoing medical management of underlying allergic rhinitis remains important to prevent recurrent turbinate hypertrophy.